Salud financiera de hoja de balance de HABA LaboratoriesInc

Salud financiera controles de criterios 3/6

HABA LaboratoriesInc tiene un patrimonio de los accionistas total de ¥9.7B y una deuda total de ¥2.6B, lo que sitúa su ratio deuda-patrimonio en 26.6%. Sus activos y pasivos totales son ¥14.2B y ¥4.5B respectivamente.

Información clave

26.6%

Ratio deuda-patrimonio

JP¥2.59b

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	JP¥3.77b
Patrimonio	JP¥9.71b
Total pasivo	JP¥4.49b
Activos totales	JP¥14.20b

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Feb 19

Recent updates

What Type Of Returns Would HABA LaboratoriesInc's(TYO:4925) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 09

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Feb 19

Should You Be Impressed By HABA LaboratoriesInc's (TYO:4925) Returns on Capital?

Feb 01

Is HABA Laboratories,Inc. (TYO:4925) A Smart Choice For Dividend Investors?

Jan 13

HABA Laboratories,Inc.'s (TYO:4925) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Dec 25

What Kind Of Investors Own Most Of HABA Laboratories,Inc. (TYO:4925)?

Dec 07

A Look At HABA LaboratoriesInc's (TYO:4925) Share Price Returns

Nov 19

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (¥9.2B) de 4925 superan a sus pasivos a corto plazo (¥3.3B).

Pasivo a largo plazo: Los activos a corto plazo de 4925 (¥9.2B) superan a sus pasivos a largo plazo (¥1.2B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 4925 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 4925 ha crecido de 17.7% a 26.6% en los últimos 5 años.

Cobertura de la deuda: El flujo de caja operativo de 4925 es negativo, por lo que la deuda no está bien cubierta.

Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de 4925 sobre su deuda están bien cubiertos por el EBIT.

Salud financiera de hoja de balance de HABA LaboratoriesInc

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Haba Laboratories Ordinary Shares to Be Deleted from Other OTC

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Recent updates

HABA Laboratories,Inc., Annual General Meeting, Jun 23, 2024

HABA Laboratories,Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Upcoming dividend of JP¥40.00 per share

Third quarter 2024 earnings released: JP¥150 loss per share (vs JP¥153 loss in 3Q 2023)

HABA Laboratories,Inc. to Report Q3, 2024 Results on Feb 09, 2024

Second quarter 2024 earnings released: JP¥34.38 loss per share (vs JP¥23.80 loss in 2Q 2023)

HABA Laboratories,Inc. to Report Q2, 2024 Results on Nov 10, 2023

First quarter 2024 earnings released: JP¥56.86 loss per share (vs JP¥37.02 loss in 1Q 2023)

HABA Laboratories,Inc. to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: JP¥187 loss per share (vs JP¥71.14 loss in FY 2022)

Full year 2023 earnings released: JP¥187 loss per share (vs JP¥71.14 loss in FY 2022)

HABA Laboratories,Inc., Annual General Meeting, Jun 18, 2023

Upcoming dividend of JP¥40.00 per share at 1.7% yield

Third quarter 2023 earnings released: JP¥153 loss per share (vs JP¥17.19 loss in 3Q 2022)

HABA Laboratories,Inc. to Report Q3, 2023 Results on Feb 10, 2023

Second quarter 2023 earnings released: JP¥23.80 loss per share (vs JP¥49.98 loss in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: JP¥23.80 loss per share (vs JP¥49.98 loss in 2Q 2022)

HABA Laboratories,Inc. to Report Q2, 2023 Results on Nov 11, 2022

First quarter 2023 earnings released: JP¥37.02 loss per share (vs JP¥72.72 loss in 1Q 2022)

Haba Laboratories Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released: JP¥71.14 loss per share (vs JP¥57.12 profit in FY 2021)

HABA Laboratories,Inc. to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: JP¥71.14 loss per share (vs JP¥57.12 profit in FY 2021)

HABA Laboratories,Inc., Annual General Meeting, Jun 19, 2022

Less than half of directors are independent

HABA Laboratories,Inc. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥40.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: JP¥49.98 loss per share (vs JP¥1.59 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥72.72 loss per share (vs JP¥51.57 loss in 1Q 2021)

Full year 2021 earnings released: EPS JP¥57.12 (vs JP¥339 in FY 2020)

Full year 2021 earnings released: EPS JP¥57.12 (vs JP¥339 in FY 2020)

Upcoming dividend of JP¥40.00 per share

What Type Of Returns Would HABA LaboratoriesInc's(TYO:4925) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

New 90-day high: JP¥4,515

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS JP¥30.15 (vs JP¥42.27 in 3Q 2020)

New 90-day high: JP¥4,350

Should You Be Impressed By HABA LaboratoriesInc's (TYO:4925) Returns on Capital?

Is HABA Laboratories,Inc. (TYO:4925) A Smart Choice For Dividend Investors?

HABA Laboratories,Inc. to Report Q3, 2021 Results on Feb 12, 2021

HABA Laboratories,Inc.'s (TYO:4925) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

What Kind Of Investors Own Most Of HABA Laboratories,Inc. (TYO:4925)?

A Look At HABA LaboratoriesInc's (TYO:4925) Share Price Returns

Second quarter 2021 earnings released: JP¥1.59 loss per share

New 90-day low: JP¥4,055

HABA Laboratories,Inc. to Report Q2, 2021 Results on Nov 11, 2020

First quarter earnings released

New 90-day low - JP¥4,060

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera